Clinical Trial Update: A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AR-12286 ophthalmic solution at 0.5% and 0.7% for uncontrolled advanced glaucoma in patients with prior failed trabeculectomy or tube s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma

Drugs mentioned

• AR-12286 ophthalmic solution (0.5% and 0.7%) (AR-12286)

Snippet

Sponsor: New York Glaucoma Research Institute | Conditions: Advanced Glaucoma | Phase 2 | Status: UNKNOWN